Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05658913 · ClinicalTrials.gov registry record
Tau PET/CT Imaging in the Mismatch Prospective Cohort Study (MPC-TAU)
A clinical trial of Alzheimers Disease, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- 100
- Enrollment target
- 2
- Study locations
NCT05658913: Recruiting study of Alzheimers Disease, sponsored by University of Pennsylvania.
NCT05658913 is a study of Alzheimers Disease that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 100 participants, below the 4,061-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05658913, a study of Alzheimers Disease, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 2
- Study locations
Study Summary
To collect Tau PET/CT imaging in older adults diagnosed with Mild Cognitive Impairment (MCI) or Alzheimer's Disease (AD) in the Mismatch Prospective Cohort Study (MPC-Tau) study to determine relationship to clinical, cognitive, and other biomarker data. Findings from this study will likely provide insight into the phenotypic variability of Alzheimer's Disease and other related pathologies.
Conditions Studied
Interventions
- DRUG AV-1451
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-03-14 |
| Est. Completion | 2029-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05658913
The ClinicalTrials.gov registry entry for NCT05658913 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,061-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (98% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 1 intervention - of which AV-1451 is the first listed.
NCT05658913 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05658913 about?
NCT05658913 is a clinical study titled "Tau PET/CT Imaging in the Mismatch Prospective Cohort Study (MPC-TAU)". To collect Tau PET/CT imaging in older adults diagnosed with Mild Cognitive Impairment (MCI) or Alzheimer's Disease (AD) in the Mismatch Prospective Cohort Study (MPC-Tau) study to determine relationship to clinical, cognitive, and other biomarker data. Findings from this study will likely provide i...
What is the current status of trial NCT05658913?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2023-03-14. Estimated completion is 2029-12.
What conditions does trial NCT05658913 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT05658913?
The interventions under investigation include: AV-1451 (DRUG).
Who is sponsoring clinical trial NCT05658913?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05658913 being conducted?
This trial has 2 study locations across Massachusetts, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
RECRUITING · Phase 3
-
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
RECRUITING · Phase 2
-
University of Central Florida Music Study
RECRUITING · NA
-
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
RECRUITING · Phase 3
-
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
RECRUITING · Phase 3
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.